BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1327 related articles for article (PubMed ID: 28624483)

  • 1. Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction.
    Tromp J; Khan MAF; Mentz RJ; O'Connor CM; Metra M; Dittrich HC; Ponikowski P; Teerlink JR; Cotter G; Davison B; Cleland JGF; Givertz MM; Bloomfield DM; Van Veldhuisen DJ; Hillege HL; Voors AA; van der Meer P
    JACC Heart Fail; 2017 Jul; 5(7):507-517. PubMed ID: 28624483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome.
    Farmakis D; Simitsis P; Bistola V; Triposkiadis F; Ikonomidis I; Katsanos S; Bakosis G; Hatziagelaki E; Lekakis J; Mebazaa A; Parissis J
    Clin Res Cardiol; 2017 May; 106(5):359-368. PubMed ID: 27999929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction.
    Tromp J; Khan MA; Klip IT; Meyer S; de Boer RA; Jaarsma T; Hillege H; van Veldhuisen DJ; van der Meer P; Voors AA
    J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28360225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction.
    Moliner P; Lupón J; Barallat J; de Antonio M; Domingo M; Núñez J; Zamora E; Galán A; Santesmases J; Pastor C; Bayes-Genis A
    Int J Cardiol; 2018 Apr; 257():188-192. PubMed ID: 29415801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan.
    Shiga T; Suzuki A; Haruta S; Mori F; Ota Y; Yagi M; Oka T; Tanaka H; Murasaki S; Yamauchi T; Katoh J; Hattori H; Kikuchi N; Watanabe E; Yamada Y; Haruki S; Kogure T; Suzuki T; Uetsuka Y; Hagiwara N;
    ESC Heart Fail; 2019 Jun; 6(3):475-486. PubMed ID: 30829002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
    Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
    J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.
    Sartipy U; Dahlström U; Fu M; Lund LH
    JACC Heart Fail; 2017 Aug; 5(8):565-574. PubMed ID: 28711451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study.
    Tsuji K; Sakata Y; Nochioka K; Miura M; Yamauchi T; Onose T; Abe R; Oikawa T; Kasahara S; Sato M; Shiroto T; Takahashi J; Miyata S; Shimokawa H;
    Eur J Heart Fail; 2017 Oct; 19(10):1258-1269. PubMed ID: 28370829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain).
    Farré N; Lupon J; Roig E; Gonzalez-Costello J; Vila J; Perez S; de Antonio M; Solé-González E; Sánchez-Enrique C; Moliner P; Ruiz S; Enjuanes C; Mirabet S; Bayés-Genís A; Comin-Colet J;
    BMJ Open; 2017 Dec; 7(12):e018719. PubMed ID: 29273666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction.
    Tromp J; Westenbrink BD; Ouwerkerk W; van Veldhuisen DJ; Samani NJ; Ponikowski P; Metra M; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Lang CC; Ng LL; Zannad F; Zwinderman AH; Hillege HL; van der Meer P; Voors AA
    J Am Coll Cardiol; 2018 Sep; 72(10):1081-1090. PubMed ID: 30165978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF).
    Rickenbacher P; Kaufmann BA; Maeder MT; Bernheim A; Goetschalckx K; Pfister O; Pfisterer M; Brunner-La Rocca HP;
    Eur J Heart Fail; 2017 Dec; 19(12):1586-1596. PubMed ID: 28295985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different relationships between pulse pressure and mortality in heart failure with reduced, mid-range and preserved ejection fraction.
    Teng TK; Tay WT; Dahlstrom U; Benson L; Lam CSP; Lund LH
    Int J Cardiol; 2018 Mar; 254():203-209. PubMed ID: 29407092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive population-based characterization of heart failure with mid-range ejection fraction.
    Koh AS; Tay WT; Teng THK; Vedin O; Benson L; Dahlstrom U; Savarese G; Lam CSP; Lund LH
    Eur J Heart Fail; 2017 Dec; 19(12):1624-1634. PubMed ID: 28948683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction.
    Gohar A; Chong JPC; Liew OW; den Ruijter H; de Kleijn DPV; Sim D; Yeo DPS; Ong HY; Jaufeerally F; Leong GKT; Ling LH; Lam CSP; Richards AM
    Eur J Heart Fail; 2017 Dec; 19(12):1638-1647. PubMed ID: 28849609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study.
    Lam CSP; Gamble GD; Ling LH; Sim D; Leong KTG; Yeo PSD; Ong HY; Jaufeerally F; Ng TP; Cameron VA; Poppe K; Lund M; Devlin G; Troughton R; Richards AM; Doughty RN
    Eur Heart J; 2018 May; 39(20):1770-1780. PubMed ID: 29390051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China].
    Wang H; Li YY; Chai K; Zhang W; Li XL; Dong YG; Zhou JM; Huo Y; Yang JF
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):865-874. PubMed ID: 31744275
    [No Abstract]   [Full Text] [Related]  

  • 17. Outcomes of de novo and acute decompensated heart failure patients according to ejection fraction.
    Choi KH; Lee GY; Choi JO; Jeon ES; Lee HY; Cho HJ; Lee SE; Kim MS; Kim JJ; Hwang KK; Chae SC; Baek SH; Kang SM; Choi DJ; Yoo BS; Kim KH; Park HY; Cho MC; Oh BH
    Heart; 2018 Mar; 104(6):525-532. PubMed ID: 28982721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction.
    Chen X; Savarese G; Dahlström U; Lund LH; Fu M
    Clin Res Cardiol; 2019 Dec; 108(12):1394-1405. PubMed ID: 30980205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A retrospective analysis of clinical characteristics and outcomes of heart failure patients with different left ventricular ejection fractions].
    Zhou HB; An DQ; Zhan Q; Liu ZH; Hua JH; Lai WY; Huang YL; Zeng QC; Xu DL
    Zhonghua Nei Ke Za Zhi; 2017 Apr; 56(4):253-257. PubMed ID: 28355716
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction.
    Abdul-Rahim AH; Shen L; Rush CJ; Jhund PS; Lees KR; McMurray JJV;
    Eur J Heart Fail; 2018 Jul; 20(7):1139-1145. PubMed ID: 29493058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.